Alkermes plc – A Global Biopharmaceutical Company

About Us

About Alkermes

Our Company Message From the CEO

Leadership

Management Team Board of Directors

Collaborations

Strategic Partners

Other Information

Locations

Products

Our Products

Products Overview

Key Products

United States European Union

Research & Development

R&D Overview Our R&D Approach Pipeline Technology Platforms Manufacturing

Other Information

Clinical Trials Investigator Initiated Trials Medical Education Grants

Contract Services

Why Work With Us? Our Promise to Our Partners Our Partners

Capabilities

Capabilities Overview Range of Services Publications

Investors

Corporate Overview Press Releases Investor Events Stock Information SEC Filings Annual Reports

Financials

Snapshot Trading Statistics

Other Information

Email Alerts

News & Events

Press Releases Company Events Media Kit

Careers

Working At Alkermes Meet Alkermes Employees Search Jobs Benefits Employee FAQs

Latest News

Alkermes Announces Positive Results of Phase 2 Clinical Trial of ALKS 3831 in Schizophrenia Read More
Alkermes’ Corporate Presentation to be Webcast at the 33rd Annual J.P. Morgan Healthcare Conference Read More
Alkermes Announces Positive Results From Study of ALKS 5461 for Treatment of Major Depressive Disorder Read More